Navigation Links
Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
Date:5/5/2008

Presentation Scheduled for Wednesday, May 7th at 9:30am EDT

NEW YORK, May 5 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, is scheduled to present at the Deutsche Bank 33rd Annual Health Care Conference in Boston, Massachusetts.

Mr. Weiss' presentation, which will take place on Wednesday, May 7th at 9:30am EDT, will be webcast live and will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, or ESRD. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell surviva
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals Receives Nasdaq Notification
2. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
3. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
4. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
5. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
7. Keryx Biopharmaceuticals Announces Additions to Management Team
8. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
9. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
11. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... Advance Nanotech, Inc.,(OTC Bulletin Board: AVNA), announced ... received an order from SELEX GALILEO,totaling $629,000. SELEX ... Aerospace and Defense organizations, is a leader in,surveillance, ... This contract marks the third order in 18 ...
... 24 Sun Pharmaceutical,Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP ... Dr. Barrie Levitt, Chairman of the Board,of Directors of ... to Dr. Levitt,s letter of June 19, 2008 to ... Pharma and the Initiating,Motion filed by Taro in the ...
... Knowledge Enterprises,Inc. announced today that attendance from orthopaedic ... Technology Exposition and,Conference (OMTEC) was up more than ... on the initial feedback from attendees and exhibitors,alike, ... secured a permanent position,in the orthopaedic industry as ...
Cached Biology Technology:Advance Nanotech's Owlstone Subsidiary Receives a $629,000 Order From Selex Galileo 2Advance Nanotech's Owlstone Subsidiary Receives a $629,000 Order From Selex Galileo 3Advance Nanotech's Owlstone Subsidiary Receives a $629,000 Order From Selex Galileo 4Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 2Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 3Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 4Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 5Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 6Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 7OMTEC 2008 Boasts Record Attendance and Secures Premier Position as Must-attend for Orthopaedic Companies 2
(Date:4/15/2014)... In a study of nearly 1,000 mother-child pairs, ... found that prenatal exposure to selective serotonin reuptake ... anxiety and other disorders, was associated with autism ... boys. The study, published in the online edition ... samples of ASD and DD cases, and population-based ...
(Date:4/15/2014)... study the deadliest infectious diseases recognized the contributions of ... the University of Texas Medical Branch, with a Lifetime ... Filoviruses. The filoviruses include Ebola and Marburg viruses that ... infected. The current outbreak of Ebola virus raging in ... far. , "This award represents the culmination of ...
(Date:4/15/2014)... CAMBRIDGE, MA -- Delivering chemotherapy drugs in nanoparticle form ... directly to the tumors. In recent years, scientists have ... but it has been difficult to design particles ... precise ratio. , Now MIT chemists have devised a ... easier to include three or more different drugs. In ...
Breaking Biology News(10 mins):Study: SSRI use during pregnancy associated with autism and developmental delays in boys 2International research group recognizes UTMB experts 2International research group recognizes UTMB experts 3Targeting cancer with a triple threat 2Targeting cancer with a triple threat 3
... step closer to understanding what drives tumor metastasis, as ... can slow their own growth. In a recent ... the American Association for Cancer Research, Ral A. Ruggiero, ... medicine at the National Academy of Medicine in Buenos ...
... from preclinical studies in a skin cancer model ... first-generation BRAF inhibitors used in combination with an ... potential to prevent drug-induced skin lesions in BRAF ... studies, presented at the AACR-NCI-EORTC International Conference: Molecular ...
... pollution and other particulate matter in the atmosphere can strongly ... regions or seasons, while increasing rain, snowfall and the intensity ... new study by a University of Maryland-led team of researchers. ... how aerosols -- soot, dust and other small particles in ...
Cached Biology News:New approaches may prevent certain side effects in BRAF mutation-positive melanoma 2Rising air pollution worsens drought, flooding, UMD-led study shows 2Rising air pollution worsens drought, flooding, UMD-led study shows 3Rising air pollution worsens drought, flooding, UMD-led study shows 4
... Jouan RCT series of refrigerated cold traps ... trapping of low volatility/aqueous solvents or high ... and other vacuum concentrators/centrifugal evaporators. Also used ... systems such as used in electron microscopes. ...
... Vapor Trap is specifically designed for ... such as DMSO and DMF in ... temperature refrigeration system set at -5 ... for DMSO, while completely eliminating the ...
96 Well Plate Sterile, RE bottom; consistent medium binding affinity for hydrophobic complexes and proteins....
Thermo Forma provides an array of accessory Racks for the Cryo/CryoPlus 16" Diameter storage system. To maximise inventory capacity a Jumbo Arrowhead configuration is recommended. You may choose betw...
Biology Products: